FDA approves once-weekly dosing of Amgen's Kyprolis

Amgen Inc. (NASDAQ:AMGN) said FDA approved an sNDA for a once-weekly 70 mg/m² dosing option for Kyprolis carfilzomib in combination with dexamethasone to treat relapsed or refractory multiple myeloma. The selective proteasome inhibitor is already approved as a twice-weekly 27 mg/m² dose...